Medication-info.com Search Menu

Ilumya (Tildrakizumab): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
100 mg/mL
Drug class:
Active ingredient:
Similar drugs:

Source: FDA drug labeling via NLM DailyMed · About this document

Patient information: uses, side effects, how to take - Ilumya

What is the most important information I should know about ILUMYA?

ILUMYA may cause serious side effects, including:

Serious allergic reactions. Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

  • feel faint
  • swelling of your face, eyelids, lips, mouth, tongue or throat
  • skin rash
  • trouble breathing or throat tightness
  • chest tightness

Infections. ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA.

Tell your healthcare provider right away if you have an infection or develop symptoms of an infection, including:

  • fever, sweats, or chills
  • cough
  • shortness of breath
  • blood in your phlegm (mucus)
  • muscle aches
  • warm, red, or painful skin or sores on your body different from your psoriasis
  • weight loss
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than normal

See “What are the possible side effects of ILUMYA?” for more information about side effects.

What is ILUMYA?

ILUMYA is a prescription medicine used to treat moderate to severe plaque psoriasis in adults who may benefit from taking injections, pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

It is not known if ILUMYA is safe and effective in children under 18 years of age.

Do not use ILUMYA if you have had a severe allergic reaction to tildrakizumab or any of the other ingredients in ILUMYA. See the end of this Medication Guide for a complete list of ingredients in ILUMYA.

Before receiving ILUMYA, tell your healthcare provider about all of your medical conditions, including if you:

  • have any of the conditions or symptoms listed in the section “What is the most important information I should know about ILUMYA?”
  • have an infection that does not go away or that keeps coming back
  • have TB or have been in close contact with someone with TB
  • recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA.

  • are pregnant or plan to become pregnant. It is not known if ILUMYA can harm your unborn baby.

    • There is a pregnancy exposure registry for women who become pregnant during treatment with or exposed to ILUMYA during pregnancy. If you become pregnant during treatment with ILUMYA, you can enroll in the pregnancy registry. The purpose of this registry is to collect information about the health of women exposed to ILUMYA and their baby. Talk with your healthcare provider or call 1-866-626-6847 to enroll in this registry or visit https://mothertobaby.org/ongoing-study/ilumya-tildrakizumab-asmn.

  • are breastfeeding or plan to breastfeed. It is not known if ILUMYA passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive ILUMYA?

  • ILUMYA should only be given to you by a healthcare provider.
  • ILUMYA is given as an injection under your skin (subcutaneous injection) in areas of your body such as your thighs, stomach area (abdomen), or upper arm.
  • If you miss a follow-up appointment and do not receive your dose of ILUMYA, schedule another appointment as soon as possible.

What are the possible side effects of ILUMYA?

ILUMYA may cause serious side effects. See “What is the most important information I should know about ILUMYA?”

The most common side effects of ILUMYA include:

  • upper respiratory infections
  • injection site reactions
  • diarrhea

These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of ILUMYA.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider for information about ILUMYA that is written for health professionals.

What are the ingredients in ILUMYA?

Active ingredient: tildrakizumab-asmn

Inactive ingredients: L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose, and Water for Injection, USP.

Manufactured by: Sun Pharmaceutical Industries Limited

Mumbai, Maharashtra India 400 063

U.S. License No. 2092

U.S. Patent No. 8,404,813; 8,293,883 and 9,809,648

Tildrakizumab-asmn (active ingred.) Product of South Korea.

Distributed by:

Sun Pharmaceutical Industries, Inc.

Cranbury, NJ 08512

ILUMYA is a registered trademark of Sun Pharmaceutical Industries Limited

© 2026 Sun Pharmaceutical Industries Limited

All rights reserved

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Revised: 07/2026

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: BLA 761067 · View the label on DailyMed

Revision date stated in the text: July 2026

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Ilumya

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Drug class Interleukin-23 Antagonist
Active ingredient Tildrakizumab 100 mg/mL
Dosage form Injection, solution
Route Subcutaneous
Marketing status not in the current FDA NDC Directory
Company (applicant) SUN PHARMA GLOBAL
FDA approval BLA 761067Biologics License Application (BLA) Approved March 20, 2018
Manufacturers 1 labelers list this drug on DailyMed
Packages (NDC)
Package
100 mg/mL – 1 ml in 1 carton NDC 47335-177-10
100 mg/mL – 1 ml in 1 syringe, glass NDC 47335-177-01
100 mg/mL – 1 ml in 1 carton NDC 47335-177-95
100 mg/mL – 1 ml in 1 syringe, glass NDC 47335-177-96

Source: FDA drug labeling via NLM DailyMed, data as of November 5, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.